Valproic acid toxicity: Overview and management

Journal of Toxicology - Clinical Toxicology

Volumn 40, Issue 6, 2002, Pages 789-801

  Sztajnkrycer, Matthew D ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Carnitine; Cerebral edema; Hyperammonemia; Toxicology; Valproic acid

Indexed keywords

4 AMINOBUTYRIC ACID; ACTIVATED CARBON; CARNITINE; NALOXONE; SODIUM CHANNEL; VALPROIC ACID;

AIRWAY; BLOOD TOXICITY; BRAIN EDEMA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL FEATURE; COMA; DRUG ABSORPTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERAMMONEMIA; INTOXICATION; LIVER TOXICITY; NONHUMAN; PANCREATITIS; RESPIRATION DEPRESSION; REVIEW; SUPPLEMENTATION;

ANIMALS; ANTICONVULSANTS; ANTIDOTES; BIOTRANSFORMATION; HUMANS; POISONING; RENAL DIALYSIS; UNITED STATES; VALPROIC ACID;

EID: 0036443425     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-120014645     Document Type: Review

References (110)

1. Pinkston, R.; Walker, L.A. Multiorgan system failure caused by valproic acid toxicity. Am. J. Emerg. Med. 1997, 15, 504-506.
2. Davis, L.L.; Ryan, W.; Adinoff, B.; Petty, F. Comprehensive review of the psychiatric uses of valproate. J. Clin. Psychopharmacol. 2000, 20 (Suppl. 1), 1S-7S.
3. Evans, D.L. Bipolar disorder: Diagnostic challenges and treatment considerations. J. Clin. Psychiatry 2000, 61 (Suppl. 13), 26-31.
4. Goldberg, J.F. Treatment guidelines: Current and future management of bipolar disorder. J. Clin. Psychiatry 2000, 61 (Suppl. 13), 12-18.
5. Nemeroff, C.B. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J. Clin. Psychiatry 2000, 61 (Suppl. 13), 19-25.
6. Mathew, N.T.; Kailasam, J.; Meadors, L.; Chernyschev, O.; Gentry, P. Intravenous valproate sodium (Depacon) aborts migraine rapidly: A preliminary report. Headache 2000, 40, 720-723.
7. Norton, J. Use of intravenous valproate sodium in status migraine. Headache 2000, 40, 755-757.
8. Kinze, S.; Clauss, M.; Reuter, U.; Wolf, T.; Dreier, J.P.; Einhaupl, K.M.; Arnold, G. Valproic acid is effective in migraine prophylaxis at low serum levels: A prospective open-label study. Headache 2001, 41, 774-778.
9. Hardy, J.R.; Rees, E.A.J.; Gwilliam, B.; Ling, J.; Broadley, K.; A'Hern, R. A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J. Pain Symptom Manag. 2001, 21, 204-209.
10. Litovitz, T.L.; Klein-Schwartz, W.; White, S.; Cobaugh, D.J.; Youniss, J.; Omslaer, J.C.; Drab, A.; Benson, B.E. 2000 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 2001, 19, 337 -395.
11. Litovitz, T.L.; Felberg, L.; White, S.; Klein-Schwartz, W. 1995 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 1996, 14, 487-537.
12. Litovitz, T.L.; Bailey, K.M.; Schmitz, B.F.; Holm, K.C.; Klein-Schwartz, W. 1990 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am. J. Emerg. Med. 1991, 9, 461-509.
13. Klotz, U.; Antonin, K.H. Pharmacokinetics and bioavailability of sodium valproate. Clin. Pharmacol. Ther. 1977, 21, 736-743.
14. Kandrotas, R.J.; Love, J.M.; Gal, P.; Oles, K.S. The effect of hemodialysis and hemoperfusion on serum valproic acid concentration. Neurology 1990, 40, 1456-1458.
15. Nau, H.; Loscher, W. Valproic acid and metabolites: Pharmacological and toxicological studies. Epilepsia 1984, 25 (1), S14-S22.
16. Kane, S.L.; Constantiner, M.; Staubus, A.E.; Meinecke, C.D.; Sedor, J.R. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann. Pharmacother. 2000, 34, 1146-1151.
17. Farrar, H.C.; Herold, D.A.; Reed, M.D. Acute valproic acid intoxication: Enhanced drug clearance with oral-activated charcoal. Crit. Care Med. 1993, 21, 299-301.
18. Al-Shareef, A.; Buss, D.C.; Shetty, H.G.M.; Ali, N.; Routledge, P.A. The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. Br. J. Clin. Pharmacol. 1997, 43, 109-111.
19. Graudins, A.; Aaron, C.K. Delayed peak serum valproic acid in massive divalproex overdose-treatment with charcoal hemoperfusion. J. Toxicol. Clin. Toxicol. 1996, 34, 335-341.
20. Duarte, J.; Macias, S.; Coria, F.; Fernandez, E.; Claveria, L.E. Valproate-induced coma: Case report and literature review. Ann. Pharmacother. 1993, 27, 582-583.
21. Tatsuhara, T.; Muro, H.; Matsuda, Y.; Imai, Y. Determination of valproic acid and it metabolites by gas chromatography-mass spectrometry with selected ion monitoring. J. Chromatogr. 1987, 399, 183-195.
22. Hamer, H.M.; Knake, S.; Schomburg, M.A.; Rosenow, F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000, 54, 230-232.
23. Spiller, H.A.; Krenzelok, E.P.; Klein-Schwartz, W.; Winter, M.L.; Weber, J.A.; Sollee, D.R.; Bangh, S.A.; Griffith, J.R. Multicenter case series of valproic acid ingestion. J. Toxicol. Clin. Toxicol. 1999, 37, 637.
24. Ingels, M.; Johnson, C.; Rangan, C.; Cantrell, L.; Beauchamp, J.; Clark, R.F. Retrospective study of delayed valproic acid toxicity. Acad. Emerg. Med. 2000, 7, 499.
25. Franssen, E.J.; van Essen, G.G.; Portman, A.T.; de Jong, J.; Go, G.; Stegeman, C.A.; Uges, D.R. Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. Ther. Drug Monit. 1999, 21, 289-292.
26. Dupuis, R.E.; Lichtman, S.N.; Pollack, G.M. Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf. 1990, 5, 65-71.
27. Chadwick, D.W. Concentration-effect relationships of valproic acid. Clin. Pharmacokinet. 1985, 10, 155-163.
28. Andersen, G.; Ritland, S. Life threatening intoxication with sodium valproate. J. Toxicol. Clin. Toxicol. 1995, 33, 279-284.
29. Johnson, L.Z.; Martinez, I.; Fernandez, M.C.; Davis, C.P.; Kasinath, B.S. Successful treatment of valproic acid overdose with hemodialysis. Am. J. Kidney Dis. 1999, 33, 786-789.
30. Mortensen, P.B.; Hansen, H.E.; Pedersen, B.; Hartmann-Andersen, F.; Husted, S.E. Acute valproate intoxication: Biochemical investigations and hemodialysis treatment. Int. J. Clin. Pharmacol. Ther. Toxicol. 1983, 21, 64-68.
31. Nau, H.; Wittfoht, W. Valproic acid and several metabolites: Quantitative determination in serum, urine, breast milk, and tissues by gas chromatography-mass spectrometry using selected ion monitoring. J. Chomatogr. 1981, 226, 69-78.
32. Jakobs, C.; Loscher, W. Identification of metabolites of valproic acid in serum of humans, dog, rat, and mouse. Epilepsia 1978, 19, 591-602.
33. Cotariu, D.; Zaidman, J.L. Valproic acid and the liver. Clin. Chem. 1988, 34 (5), 890-897.
34. Raskind, J.Y.; El-Chaar, G.M. The role of carnitine supplementation during valproic acid therapy. Ann. Pharmacother. 2000, 34, 630-638.
35. Ishikura, H.; Matsuo, N.; Matsubara, M.; Ishihara, T.; Takeyama, N.; Tanaka, T. Valproic acid overdose and L-carnitine therapy. J. Anal. Toxicol. 1996, 20, 55-58.
36. Johannessen, C.U. Mechanisms of action of valproate: A commentatory. Neurochem. Int. 2000, 37, 103-110.
37. McLean, M.J.; MacDonald, R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 1986, 237, 1001-1011.
38. Farrant, M.; Webster, R.A. Neuronal activity, amino acid concentration, and amino acid release in the substantia nigra of the rat after sodium valproate. Brain Res. 1986, 386, 1-11.
39. Albus, H.; Williamson, R. Electrophysical analysis of the action of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia 1998, 39, 124-139.
40. Hariton, C.; Ciesielski, L.; Simler, S.; Valli, M.; Jadot, G.; Gobaille, S.; Mesdjian, E.; Mandel, P. Distribution of sodium valproate and GABa metabolism in CNS of the rat. Biopharm. Drug Dispos. 1984, 5, 409-414.
41. Keane, P.E.; Simiand, J.; Morre, M. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice. Methods Find. Exp. Clin. Pharmacol. 1985, 7, 83-86.
42. Keane, P.E.; Morre, M. Effect of valproate on brain GABA: Comparison with various medium chain fatty acids. Pharmacol. Res. Commun. 1985, 17, 547-555.
43. Swann, A.C. Major Systemic Toxicities and Side Effects of Anticonvulsants. J. Clin. Psychiatry 2001, 62 (Suppl. 14), 16-21.
44. Khoo, S.H.; Leyland, M.J. Cerebral edema following acute sodium valproate overdose. J. Toxicol. Clin. Toxicol. 1992, 30, 209-214.
45. Matsumoto, J.; Ogawa, H.; Maeyama, R.; Okudaira, K.; Shinka, T.; Kuhara, T.; Matsumoto, I. Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication. Epilepsia 1997, 38, 950-953.
46. Triggs, W.J.; Gilmore, R.L.; Millington, D.S.; Cibula, J.; Bunch, T.S.; Harman, E. Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. Int. J. Clin. Pharmacol. Ther. 1997, 35, 353 -356.
47. Janssen, F.; Rambeck, B.; Schnabel, R. Acute valproate intoxication with fatal outcome in an infant. Neuropediatrics 1985, 16, 235-238.
48. Berthelot-Moritz, F.; Chadda, K.; Chanavaz, I.; Leroy, J.P.; Droy, J.M.; Bonmarchand, G.; Leroy, J. Fatal sodium valproate poisoning. Intensive Care Med. 1997, 23, 599.
49. Loscher, W.; Nau, H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 1985, 24, 427-435.
50. Murakami, K.; Sugimoto, T.; Woo, M.; Nishida, N.; Muro, H. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 1996, 37, 687-689.
51. Blei, A.T. Pathophysiology of brain edema in fulminant hepatic failure, Revisited. Metab. Brain Dis. 2001, 16, 85-94.
52. Albrecht, J.; Dolinska, M. Glutamine as a pathogenic factor in hepatic encephalopathy. J. Neurosci. Res. 2001, 65, 1-5.
53. Hertz, L.; Yu, A.C.H.; Kala, G.; Schousboe, A. Neuronal-astrocytic and cytosolic-mitochondrial metabolite trafficking during brain activation, hyperammonemia, and energy deprivation. Neurochem. Int. 2000, 37, 83-102.
54. Marcaida, G.; Felipo, V.; Hermenegildo, C.; Minana, M.D.; Grisolia, S. Acute ammonia toxicity is mediated by the NMDA type of glutamate receptors. FEBS Lett. 1992, 13 (296), 67-68,
55. Connacher, A.A.; MacNab, M.S.; Moody, J.P.; Jung, R.T. Fatality due to massive overdose of sodium valproate. Scott. Med. J. 1987, 32, 85-86.
56. Camfield, P.R.; Bagnell, P.; Camfield, C.S.; Tibbles, J.A. Pancreatitis due to valproic acid. Lancet 1979, 1, 1198-1199.
57. Batalden, P.B.; Van Dyne, B.J.; Cloyd, J. Pancreatitis associated with valproic acid therapy. Pediatrics 1979, 64, 520-522.
58. Binek, J.; Hany, A.; Heer, M. Valproic-acid-induced pancreatitis: Case report and review of the literature. J. Clin. Gastroenterol. 1991, 3, 690-693.
59. Rosenberg, H.K.; Ortega, W. Hemorrhagic pancreatitis in a young child following valproic acid Therapy. Clin. Pediatr. 1987, 26, 98-101.
60. Caparros-Lefebvre, D.; Lecomte-Houcke, M.; Pruvot, F.R.; Declerck, N.; Paris, J.C.; Petit, H. Unusual electronmicroscopic changes in valproate-associated liver failure. Lancet 1993, 341, 1604.
61. Gerber, N.; Dickinson, R.G.; Harland, R.C.; Lynn, R.K.; Houghton, L.D.; Antonias, J.I.; Schimschock, J.C. Reye-like syndrome associated with valproic acid therapy. J. Pediatr. 1979, 95, 142-144.
62. Suchy, F.J.; Balistreri, W.F.; Buchino, J.J.; Sondheimer, J.M.; Bates, S.R.; Kearns, G.L.; Stull, J.D.; Bove, K.E. Acute hepatic failure associated with the use of sodium valproate. N. Engl. J. Med. 1979, 300, 962-966.
63. Appleton, R.E.; Farrell, K.; Applegarth, D.A.; Dimmick, J.E.; Wong, L.T.; Davidson, A.G. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can. J. Neurol. Sci. 1990, 17, 145-148.
64. Krahenbuhl, S.; Brandner, S.; Kleinle, S.; Liechti, S.; Straumann, D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000, 20, 346-348.
65. Chabrol, B.; Mancini, J.; Chretien, D.; Rustin, P.; Munnich, A.; Pinsard, N. Valproate-induced hepatic failure in a case of cytochrome C oxidase deficiency. Eur. J. Pediatr. 1994, 153, 133-135.
66. Kochen, W.; Schneider, A.; Ritz, A. Abnormal metabolism of valproic acid in fatal hepatic failure. Eur. J. Pediatr. 1983, 141, 30-35.
67. Kuhara, T.; Inoue, Y.; Matsumoto, M.; Shinka, T.; Matsumoto, I.; Kawahara, N.; Sakura, N. Markedly increased ω-oxidation of valproate in fulminant hepatic failure. Epilepsia 1990, 31, 214-217.
68. Kesterson, J.W.; Granneman, G.R.; Machinist, J.M. The Hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984, 4, 1143-1152.
69. Rettie, A.E.; Rettenmeier, A.W.; Howald, W.N.; Baillie, T.A. Cytochrome P-450-catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 1987, 235, 890-893.
70. Kulick, S.K.; Kramer, D.A. Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. Ann. Emerg. Med. 1993, 22, 610-612.
71. Thabet, H.; Brahmi, N.; Amamou, M.; Ben Salah, N.; Hedhili, N. Hyperlactatemia and hyperammonemia as secondary effects of valproic acid poisoning. Am. J. Emerg. Med. 2000, 18, 508.
72. Lee, W.L.; Yang, C.C.; Deng, J.F.; Chen, Y.F.; Lin, H.D.; Wang, P.H. A case of severe hyperammonemia and unconsciousness following sodium valproate intoxication. Vet. Hum. Toxicol. 1998, 40, 346-348.
73. Hjelm, M.; Oberholzer, V.; Seakins, J.; Thomas, S.; Kay, J.D.S. Valproate-induced inhibition of urea synthesis and hyperammonaemia in healthy subjects. Lancet 1986, 2, 859.
74. Rawat, S.; Borkowski, W.J.; Swick, H.M. Valproic acid and secondary hyperammonemia. Neurology 1981, 31, 1173-1174.
75. Coulter, D.L. Carnitine deficiency in epilepsy: Risk factors and treatment. J. Child Neurol. 1995, 10 (Suppl. 2), S32-S39.
76. Rumbach, L.; Cremel, G.; Marescaux, C.; Warter, J.M.; Waksman, A. Valproate-induced hyperammonemia of renal origin. Effect of valproate on glutamine transport in rat kidney mitochondria. Biochem. Pharmacol. 1989, 38, 3963-3967.
77. Coulter, D.L.; Allen, R.J. Secondary Hyperammonemia: A Possible Mechanism for Valproate Encephalopathy. Lancet 1980, 1310-1311.
78. Coude, F.X.; Rabier, D.; Cathelineau, L.; Grimber, G.; Parvy, P.; Kamoun, P.P. A mechanism for valproate-induced hyperammonemia. Pediatr. Res. 1981, 15, 974-975.
79. Paganini, M.; Zaccara, G.; Moroni, F. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid. Eur. J. Clin. Pharmacol. 1987, 32, 219-222.
80. Kondo, T.; Ishida, M.; Kaneko, S.; Hirano, T.; Otani, K.; Fukushima, Y.; Muranaka, H.; Koide, N.; Yokoyama, M.; Nakata, S.; Kudo, H. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia? Epilepsia 1992, 33, 550-554.
81. Dreifuss, F.E.; Santilli, N.; Langer, D.H.; Sweeney, K.P.; Moline, K.A.; Menander, K.B. Valproic acid hepatic fatalities: A retrospective review. Neurology 1987, 37, 379-385.
82. Murakami, K.; Sugimoto, T.; Nishida, N.; Kobayashi, Y.; Kuhura, T.; Matsumoto, I. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy. Brain Dev. 1992, 14, 178-181.
83. Beversdorf, D.; Allen, C.; Nordgren, R. Valproate-induced encephalopathy treated with carnitine in an adult. J. Neurol. Neurosurg. Psychiatry 1996, 61, 211.
84. De Vivo, D.C.; Bohan, T.P.; Coulter, D.L.; Dreifuss, F.E.; Greenwood, R.S.; Nordli, D.R.; Shields, W.D.; Stafstrom, C.E.; Tein, I. L-carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia 1998, 39, 1216-1225.
85. Coulter, D.L. Carnitine, valproate and toxicity. J. Child Neurol. 1991, 6, 7-14.
86. Thom, H.; Carter, P.E.; Cole, G.F.; Stevenson, K.L. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev. Med. Child Neurol. 1991, 33, 795-802.
87. Takeuchi, T.; Sugimoto, T.; Nishida, N.; Kobayashi, Y. Protective effect of D,L-carnitine on valproate-induced hyperammonemia and hypoketonemia in primary cultured rat hepatocytes. Biochem. Pharmacol. 1988, 37, 2255-2258.
88. Ponchaut, S.; van Hoof, F.; Veitch, K. In Vitro Effects of Valproate and Valproate Metabolites on Mitochondrial Oxidations. Relevance of CoA Sequestration to the Observed Inhibitions. Biochem. Pharmacol. 1992, 43, 2435-2442.
89. Baldwin, G.S.; Abbott, F.S.; Nau, H. Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation. FEBS Lett. 1996, 384, 58-60.
90. Alonso, E.; Girbes, J.; Garcia-Espana, A.; Rubio, V. Changes in urea cycle-related metabolites in the mouse after combined administration of valproic acid and an amino acid load. Arch. Biochem. Biophys. 1989, 272, 267-273.
91. Thurston, J.H.; Carroll, J.E.; Hauhart, R.E.; Schiro, J.A. A single therapeutic dose of valproate affects liver carbohydrate, fat, adenylate, amino acid, coenzyme A, and carnitine metabolism in infant mice: Possible clinical significance. Life Sci. 1985, 36, 1643-1651.
92. Beauchamp, J.; Olson, K. Valproic Acid Overdoses: A retrospective study comparing serum drug levels and the incidence of adverse outcomes. J. Toxicol. Clin. Toxicol. 1999, 37, 637-638.
93. Roodhooft, A.M.; Van Dam, K.; Haentjens, D.; Verpooten, G.A.; Van Acker, K.J. Acute sodium valproate intoxication: Occurrence of renal failure and treatment with haemoperfusion-haemodialysis. Eur. J. Pediatr. 1990, 149, 363-364.
94. Settle, E.J., Jr. Valproic acid-associated encephalopathy with coma. Am. J. Psychiatr. 1995, 152, 1236-1237.
95. Barrueto, F., Jr.; Hack, J.B. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad. Emerg. Med. 2001, 8, 999-1001.
96. Chyka, P.A.; Seger, D. Position statement: Single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J. Toxicol. Clin. Toxicol. 1997, 35, 721-741.
97. Anon. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J. Toxicol. Clin. Toxicol. 1999, 37, 731-751.
98. Von Bardeleben, R.S.; Sturer, A.; Weilemann, L.S. Valproic acid intoxications in 96 documented cases 1995-1998: The role of hemoperfusion in therapy. J. Toxicol. Clin. Toxicol. 1998, 36, 471-472.
99. Matsumoto, J.; Ogawa, H.; Maeyama, R.; Okudaira, K.; Shinka, T.; Kuhara, T.; Matsumoto, I. Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication. Epilepsia 1997, 38, 950-953.
100. Tank, J.E.; Palmer, B.F. Simultaneous "in series" hemodialysis and hemoperfusion in the management of valproic acid overdose. Am. J. Kidney Dis. 1993, 22, 341-344.
101. Ruskoky, D.; Holmes, C.; Schauben, J. Utilization of hemodialysis to enhance valproic acid (VPA) elimination. J. Toxicol. Clin. Toxicol. 1999, 37, 636.
102. Graeme, K.; Higgins, T.; Curry, S.; Kunkel, D. Markedly elevated valproate levels do not serve as an indication for hemodialysis or hemoperfusion. J. Toxicol. Clin. Toxicol. 1999, 37, 636.
103. Steiman, G.S.; Woerpel, R.W.; Sherard, E.S., Jr. Treatment of accidental sodium valproate overdose with an opiate antagonist. Ann. Neurol. 1979, 6, 274.
104. Alberto, G.; Erickson, T.; Popiel, R.; Narayanan, M.; Hryhorczuk, D. Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann. Emerg. Med. 1989, 18, 889-891.
105. Montero, F.J. Naloxone in the reversal of coma induced by sodium valproate. Ann. Emerg. Med. 1999, 33, 357-358.
106. Espinoza, O.; Maradei, I.; Ramirez, M.; Pascuzzo-Lima, C. An unusual presentation of opioid-like syndrome in pediatric valproic acid poisoning. Vet. Hum. Toxicol. 2001, 43, 178-179.
107. Takeuchi, T.; Sugimoto, T.; Nishida, N.; Kobayashi, Y. Protective effect of D,L-carnitine on valproate-induced hyperammonemia and hypoketonemia in primary cultured rat hepatocytes. Biochem. Pharmacol. 1988, 37, 2255-2258.
108. Anon. Carnitor. Physician's Desk Reference, 54th Ed.; Medical Economic Company: Montvale, NJ, 2000.
109. Sztajnkrycer, M.D.; Seaglione, J.M.; Bond, G.R. Valproate-Induced hyperammonemia: Preliminary evaluation of ammonia elimination with carnitine administration. J. Toxicol. Clin. Toxicol. 2001, 39, 497.
110. Thole, D.; Bagnasco, T.; Lovecchio, F. Delayed Absorption of Valproic Acid Resulting in Coma. J. Toxicol. Clin. Toxicol. 2001, 39, 497.